目的： 观察人乳头瘤病毒16型（HPV）E6/E7融合蛋白疫苗与放疗（12 Gy）联合应用对宫颈癌的治疗效果。方法：24只雌性C57BL/6小鼠右侧后肢接种肿瘤细胞后7 d，随机分为4组：对照组（C，n=6）；免疫组（IM，n=6）；放疗组（RA，n=6）；联合治疗组（IM+RA，n=6）。比较各组小鼠的肿瘤生长速度及存活时间。采用TUNEL法对小鼠肿瘤组织中细胞的凋亡情况进行检测。结果： IM+RA组小鼠肿瘤生长速度较慢，平均存活时间明显长于RA、IM及C组，IM组与C组动物的平均存活时间没有差异。TUNEL实验结果表明，IM+RA组小鼠肿瘤组织中凋亡细胞明显高于其他各组。结论： HPV16E6/E7融合蛋白疫苗与放疗联合应用，具有协同抗肿瘤作用

Objective: To evaluate the therapeutic effect of combination of the human papillomavirus 16 (HPV16) E6/E7 fusion protein vaccine with radiotherapy on the HPV16-positive cervical cancer. Methods: Twenty-four female C57BL/6 mice 7 days after inoculation of tumor cells on the right hind legs were randomly divided into four groups: The control group (C, n=6); Immunotherapy group (IM, n=6); Radiotherapy group (RA, n=6); Immunotherapy+Radiotherapy (IM+RA, n=6). The growth rates of tumors and survival time were recorded and compared with each other. The apoptotic tumor cells in situ were detected by TUNEL assay. Results:The growth rates of tumors in IM+RA- group were lower than other groups. The mean survival time in IM+RA-group was longer than those in IM-, RA- and C-groups, but the difference between IM- and C- group was not significant. The result of TUNEL assay indicated that there were more apoptotic tumor cells in IM+RA- group than that in other groups. Conclusion:The combination of HPV16E6/E7 fusion protein vaccine with low dose radiotherapy exerted synergic antitumor efficacy, which might provide a new approach for the treatment of cervical cancer.

R511 R392-33

国家“863”计划项目(NO:2002AA216041)